boulder ridge semaglutide GLP-1 Treatments, Medical Weight Loss in Denver, CO Progress like this changes more

Important: The chart above reflects the approved Wegovy escalation schedule

Marietta M, Facchinetti F, Neri I, Piccinini F, Volpe A, Torelli G, et al

In STEP 1, once-weekly semaglutide 2.4 mg produced a mean weight reduction of approximately 14.9% at 68 weeks compared with placebo [1], while SURMOUNT-1 reported weight reductions approaching 20% with tirzepatide at higher doses [2]

Retatrutide: A Promising Option for Non-Diabetic Weight Loss in Clinical Trials Key Takeaways Retatrutide, a new triple receptor agonist, appears particularly promising as a non-diabetic weight loss agent because it targets glucagon, GLP-1, and GIP

Ask yourself these five questions first